½ÃÀ庸°í¼­
»óǰÄÚµå
1521384

¼¼°èÀÇ ¿ïÇ÷¼º½ÉºÎÀü Ä¡·á ±â±â ½ÃÀå Á¶»ç º¸°í¼­ : »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2024-2032³â)

Global Congestive Heart Failure Treatment Device Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Value Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 130 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¿ïÇ÷¼º½ÉºÎÀü Ä¡·á ±â±â ½ÃÀåÀÇ ¼¼°è ¼ö¿ä´Â 2023³â 282¾ï 2,000¸¸ ´Þ·¯¿¡¼­ 2032³â¿¡´Â ¾à 521¾ï 4,000¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ÃßÁ¤µÇ¸ç, Á¶»ç ±â°£ÀÎ 2024-2032³â CAGRÀº 7.06%ÀÔ´Ï´Ù.

¿ïÇ÷¼º½ÉºÎÀü(CHF) Ä¡·á ±â±â¿¡´Â ½ÉºÎÀü Áõ»óÀ» °ü¸®ÇÏ°í °³¼±Çϱâ À§ÇØ Æ¯º°È÷ °í¾ÈµÈ ´Ù¾çÇÑ ÀÇ·á±â±â°¡ Æ÷ÇԵ˴ϴÙ. ÀÌ ÀåºñµéÀº ½ÉÀåÀÌ Ç÷¾×À» È¿À²ÀûÀ¸·Î ÆßÇÁÁúÇÏ´Â µ¥ ¾î·Á¿òÀ» °Þ°í Æó¿Í ½Åü ´Ù¸¥ ºÎÀ§¿¡ ü¾×ÀÌ ÃàÀûµÇ´Â ¸¸¼ºÁúȯÀÎ CHF ȯÀڵ鿡°Ô Ä¡·áÀû Áö¿øÀ» Á¦°øÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ¿ïÇ÷¼º½ÉºÎÀü Ä¡·á ±â±âÀÇ ÁÖ¿ä ¸ñÀûÀº ½ÉÀå ±â´ÉÀ» Çâ»ó½Ã۰í Áõ»óÀ» ¿ÏÈ­Çϸç ȯÀÚÀÇ Àü¹ÝÀûÀÎ »îÀÇ ÁúÀ» Çâ»ó½ÃŰ´Â °ÍÀÔ´Ï´Ù.

½ÃÀå ¿ªÇÐ

¼¼°è ½ÉºÎÀü Ä¡·áÁ¦ ½ÃÀåÀº Àü ¼¼°è ½ÉºÎÀü À¯º´·ü Áõ°¡, ƯÈ÷ ³ëÀÎ Àα¸ Áõ°¡¿¡ ÈûÀÔ¾î Å« ÆøÀÇ ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. Æò±Õ ¼ö¸íÀÌ ±æ¾îÁö°í ¶óÀÌÇÁ½ºÅ¸ÀÏÀÌ º¯È­ÇÔ¿¡ µû¶ó ½ÉºÎÀü ¹ß»ý·üÀº °è¼Ó Áõ°¡Çϰí ÀÖÀ¸¸ç, ½É¹ÚÁ¶À²±â, À̽ÄÇü Á¦¼¼µ¿±â(ICD), ½ÉÀåÀ絿±âÈ­¿ä¹ý(CRT)°ú °°Àº À̽ÄÇü Àåºñ¸¦ Æ÷ÇÔÇÑ °í±Þ Ä¡·á ¿É¼ÇÀÌ ÇÊ¿äÇÏ°Ô µÇ¾ú½À´Ï´Ù. ½ÉÀå Ä¡·áÀÇ ±â¼ú ¹ßÀüµµ ½ÃÀå ¼ºÀå¿¡ ¸Å¿ì Áß¿äÇÑ ÃËÁø¿äÀÎÀÔ´Ï´Ù. ÀåºñÀÇ ¼ÒÇüÈ­, ¿ø°Ý ¸ð´ÏÅ͸µÀ» À§ÇÑ ¹«¼± ¿¬°á, ¹èÅ͸® ¼ö¸í °³¼± µîÀÇ ±â¼ú Çõ½ÅÀº ¿ïÇ÷¼º½ÉºÎÀü Ä¡·á ±â±âÀÇ È¿°ú¿Í »ç¿ë ÆíÀǼºÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº ÀÇ·áÁø¿¡°Ô ½Ç½Ã°£ µ¥ÀÌÅ͸¦ Á¦°øÇÔÀ¸·Î½á ȯÀÚ °á°ú¸¦ °³¼±Çϰí, °³ÀÎÈ­µÇ°í ½Ã±âÀûÀýÇÑ °³ÀÔÀ» ÅëÇØ ¸¸¼ºÁúȯÀ» ´õ Àß °ü¸®ÇÒ ¼ö ÀÖµµ·Ï µ½°í ÀÖ½À´Ï´Ù.

¶ÇÇÑ À¯¸®ÇÑ »óȯ Á¤Ã¥°ú ÀÇ·áºñ Áõ°¡·Î ÀÎÇØ ½ÃÀå È®´ë°¡ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. Á¤ºÎ¿Í ÀÇ·á ±â°üÀº ½ÉºÎÀü°ú °°Àº ¸¸¼ºÁúȯÀ» °ü¸®Çϱâ À§ÇÑ ¿¹¹æ Á¶Ä¡¿Í °í±Þ Ä¡·á ¿É¼ÇÀÇ ºñ¿ë È¿À²¼ºÀ» Á¡Á¡ ´õ ÀνÄÇϰí ÀÖÀ¸¸ç, ÀÌ´Â ¿ïÇ÷¼º½ÉºÎÀü Ä¡·á ±â±âÀÇ Ã¤ÅÃÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ³ôÀº Ãʱ⠺ñ¿ë°ú ±â±â ÀÌ½Ä ¹× À¯Áöº¸¼ö ºñ¿ë, ¾ö°ÝÇÑ ±â±â ½ÂÀÎ ¹× ȯÀÚ ¾ÈÀü °ü·Ã ±ÔÁ¦ ¿ä°ÇÀº Áß¼ÒÇü ¿ïÇ÷¼º½ÉºÎÀü Ä¡·á ±â±â Á¦Á¶¾÷ü ½ÃÀå ÁøÀÔÀ» °¡·Î¸·´Â Àå¾Ö¹°ÀÌ µÇ°í ÀÖ½À´Ï´Ù.

Á¶»ç ¸®Æ÷Æ®´Â Porter's Five Forces ¸ðµ¨, ½ÃÀåÀÇ ¸Å·Â ºÐ¼®, ¹ë·ùüÀÎ ºÐ¼®À» ´Ù·ç°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÅøÀº ¾÷°èÀÇ ±¸Á¶¸¦ ¸íÈ®ÇÏ°Ô ÆÄ¾ÇÇϰí, ¼¼°è ·¹º§¿¡¼­ÀÇ °æÀï ¸Å·ÂÀ» Æò°¡Çϴµ¥ µµ¿òÀÌ µË´Ï´Ù. ¶ÇÇÑ ÀÌ·¯ÇÑ ÅøÀº ¼¼°èÀÇ ¿ïÇ÷¼º½ÉºÎÀü Ä¡·á ±â±â ½ÃÀåÀÇ °¢ ºÎ¹®À» Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼öµµ ÀÖ½À´Ï´Ù. ¿ïÇ÷¼º½ÉºÎÀü Ä¡·á ±â±â »ê¾÷ÀÇ ¼ºÀå°ú µ¿ÇâÀº ÀÌ Á¶»ç¿¡ ÀüüÀûÀÎ ¾îÇÁ·ÎÄ¡¸¦ Á¦°øÇÕ´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­

¿ïÇ÷¼º½ÉºÎÀü Ä¡·á ±â±â ½ÃÀå º¸°í¼­ÀÇ ÀÌ ¼½¼Ç¿¡¼­´Â ±¹°¡º° ¹× Áö¿ªº° ºÎ¹®¿¡ °üÇÑ »ó¼¼ µ¥ÀÌÅ͸¦ Á¦°øÇϸç, ÀÌ¿¡ µû¶ó Àü·«°¡°¡ ÇâÈÄ ±âȸ¿Í ÇÔ²² °¢°¢ÀÇ Á¦Ç° ¹× ¼­ºñ½ºÀÇ Å¸±êÃþÀ» ½Äº°Çϴµ¥ µµ¿òÀÌ µË´Ï´Ù.

Á¦Ç°º°

  • Á¦¼¼µ¿±â(À̽ÄÇü Á¦¼¼µ¿±â(ICD)(°æÁ¤¸Æ ICD(´Ü½ÇICD, º¹½ÇICD), ÇÇÇÏ ICD))
  • ü¿Ü½Ä Á¦¼¼µ¿±â(¼öµ¿½Ä ü¿Ü½Ä Á¦¼¼µ¿±â, ÀÚµ¿½Ä ü¿Ü½Ä Á¦¼¼µ¿±â(¹ÝÀÚµ¿½Ä ü¿Ü½Ä Á¦¼¼µ¿±â, ÀüÀÚµ¿½Ä ü¿Ü½Ä Á¦¼¼µ¿±â), ÀåÂøÇü ü¿Ü½Ä Á¦¼¼µ¿±â)
  • ÆäÀ̽º¸ÞÀÌÄ¿(À̽ÄÇü ÆäÀ̽º¸ÞÀÌÄ¿, ü¿Ü½Ä ÆäÀ̽º¸ÞÀÌÄ¿)
  • ½ÉÀåÀ絿±â ¿ä¹ý Àåºñ(½ÉÀåÀ絿±â Á¦¼¼µ¿±â(CRT-D)(MRI ´ëÀÀ CRT-D Àåºñ, ±âÁ¸Çü CRT-D Àåºñ), ½ÉÀåÀ絿±â ¿ä¹ý ÆäÀ̽º Á¦Á¶¾÷ü(CRT-P)(MRI ´ëÀÀ CRT-P Àåºñ, ±âÁ¸Çü CRT-P Àåºñ))
  • º¸Á¶ Àΰø ½ÉÀå(ÁÂ½É½Ç º¸Á¶ Àΰø ½ÉÀå, ¿À¸¥ÂÊ ½É½Ç º¸Á¶ Àΰø ½ÉÀå, ¾ç½É½Ç º¸Á¶ Àΰø ½ÉÀå, °æÇÇÀû ½É½Ç º¸Á¶ Àΰø ½ÉÀå, ÀüÀΰø ½ÉÀå)
  • ±âŸ Á¦Ç°

ÃÖÁ¾»ç¿ëÀÚº°

  • º´¿ø
  • ½ÉÀå Ŭ¸®´Ð
  • ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ
  • ±âŸ ÃÖÁ¾»ç¿ëÀÚ

Áö¿ª ºÐ¼®

ÀÌ ¼½¼Ç¿¡¼­´Â ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ & ¾ÆÇÁ¸®Ä« ¿ïÇ÷¼º½ÉºÎÀü Ä¡·á ±â±â ½ÃÀåÀÇ ÇöÀç ¹× ÇâÈÄ ¼ö¿ä¸¦ °­Á¶ÇÏ´Â Áö¿ª Àü¸ÁÀ» ´Ù·ç°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ º» ¸®Æ÷Æ®´Â ¸ðµç ÁÖ¿ä Áö¿ª¿¡¼­ °³º° ¾ÖÇø®ÄÉÀÌ¼Ç ºÎ¹®ÀÇ ¼ö¿ä, ÃßÁ¤¡¤¿¹Ãø¿¡ ÃÊÁ¡À» ¸ÂÃß°í ÀÖ½À´Ï´Ù.

Ä¿½ºÅÒ ¿ä°ÇÀÌ ÀÖ´Â °æ¿ì, ¹®ÀÇÇØÁֽñ⠹ٶø´Ï´Ù. ´ç»çÀÇ Á¶»ç ÆÀÀÌ °í°´ÀÇ ¿ä±¸¿¡ µû¶ó ¸ÂÃãÇü º¸°í¼­¸¦ Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå °³¿ä

  • ½ÃÀåÀÇ ÇÏÀ̶óÀÌÆ®
  • ¼¼°è ½ÃÀå ÇöȲ

Á¦3Àå ¿ïÇ÷¼º½ÉºÎÀü Ä¡·á ±â±â - »ê¾÷ ºÐ¼®

  • ¼­·Ð - ½ÃÀå ¿ªÇÐ
  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ½ÃÀå ±âȸ
  • ¾÷°è µ¿Çâ
  • Porter's Five Forces ºÐ¼®
  • ½ÃÀåÀÇ ¸Å·Â ºÐ¼®

Á¦4Àå ¹ë·ùüÀÎ ºÐ¼®

  • ¹ë·ùüÀÎ ºÐ¼®
  • ¿øÀç·á ºÐ¼®
    • ¿øÀç·á ¸®½ºÆ®
    • ¿øÀç·á Á¦Á¶¾÷ü ¸®½ºÆ®
    • ÁÖ¿ä ¿øÀç·áÀÇ °¡°Ý µ¿Çâ
  • ÀáÀçÀû ¹ÙÀÌ¾î ¸®½ºÆ®
  • ¸¶ÄÉÆÃ Ã¤³Î
    • ´ÙÀÌ·ºÆ® ¸¶ÄÉÆÃ
    • ÀδÙÀÌ·ºÆ® ¸¶ÄÉÆÃ
    • ¸¶ÄÉÆÃ Ã¤³Î ¹ßÀü µ¿Çâ

Á¦5Àå ¼¼°èÀÇ ¿ïÇ÷¼º½ÉºÎÀü Ä¡·á ±â±â ½ÃÀå ºÐ¼® : Á¦Ç°º°

  • Á¦Ç°º° °³¿ä
  • Á¦Ç°º° °ú°Å ¹× ¿¹Ãø µ¥ÀÌÅÍ ºÐ¼®
  • Á¦¼¼µ¿±â(À̽ÄÇü Á¦¼¼µ¿±â(ICD)(°æÁ¤¸Æ ICD(´Ü½ÇICD, º¹½ÇICD), ÇÇÇÏ ICD))
  • ü¿Ü½Ä Á¦¼¼µ¿±â(¼öµ¿½Ä ü¿Ü½Ä Á¦¼¼µ¿±â, ÀÚµ¿½Ä ü¿Ü½Ä Á¦¼¼µ¿±â(¹ÝÀÚµ¿½Ä ü¿Ü½Ä Á¦¼¼µ¿±â, ÀüÀÚµ¿½Ä ü¿Ü½Ä Á¦¼¼µ¿±â), ÀåÂøÇü ü¿Ü½Ä Á¦¼¼µ¿±â)
  • ÆäÀ̽º¸ÞÀÌÄ¿(À̽ÄÇü ÆäÀ̽º¸ÞÀÌÄ¿, ü¿Ü½Ä ÆäÀ̽º¸ÞÀÌÄ¿)
  • ½ÉÀåÀ絿±â ¿ä¹ý Àåºñ(½ÉÀåÀ絿±â Á¦¼¼µ¿±â(CRT-D)(MRI ´ëÀÀ CRT-D Àåºñ, ±âÁ¸Çü CRT-D Àåºñ), ½ÉÀåÀ絿±â ¿ä¹ý ÆäÀ̽º Á¦Á¶¾÷ü(CRT-P)(MRI ´ëÀÀ CRT-P Àåºñ, ±âÁ¸Çü CRT-P Àåºñ))
  • º¸Á¶ Àΰø ½ÉÀå(ÁÂ½É½Ç º¸Á¶ Àΰø ½ÉÀå, ¿À¸¥ÂÊ ½É½Ç º¸Á¶ Àΰø ½ÉÀå, ¾ç½É½Ç º¸Á¶ Àΰø ½ÉÀå, °æÇÇÀû ½É½Ç º¸Á¶ Àΰø ½ÉÀå, ÀüÀΰø ½ÉÀå)
  • ±âŸ Á¦Ç°

Á¦6Àå ¼¼°èÀÇ ¿ïÇ÷¼º½ÉºÎÀü Ä¡·á ±â±â ½ÃÀå ºÐ¼® : ÃÖÁ¾ ¿ëµµº°

  • ÃÖÁ¾ ¿ëµµº° °³¿ä
  • ÃÖÁ¾ ¿ëµµº° °ú°Å ¹× ¿¹Ãø µ¥ÀÌÅÍ ºÐ¼®
  • º´¿ø
  • ½ÉÀå Ŭ¸®´Ð
  • ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ
  • ±âŸ ÃÖÁ¾»ç¿ëÀÚ

Á¦7Àå ¼¼°èÀÇ ¿ïÇ÷¼º½ÉºÎÀü Ä¡·á ±â±â ½ÃÀå ºÐ¼® : Áö¿ªº°

  • Áö¿ªº° Àü¸Á
  • ¼­·Ð
  • ºÏ¹Ì ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • ºÏ¹Ì : ºÎ¹®º°
    • ºÏ¹Ì ±¹°¡º°
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´ ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • À¯·´ ºÎ¹®º°
    • À¯·´ ±¹°¡º°
    • ¿µ±¹
    • ÇÁ¶û½º
    • µ¶ÀÏ
    • ÀÌÅ»¸®¾Æ
    • ·¯½Ã¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • ¾Æ½Ã¾ÆÅÂÆò¾ç ºÎ¹®º°
    • ¾Æ½Ã¾ÆÅÂÆò¾ç ±¹°¡º°
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • È£ÁÖ
    • µ¿³²¾Æ½Ã¾Æ
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä« ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • ¶óƾ¾Æ¸Þ¸®Ä« ºÎ¹®º°
    • ¶óƾ¾Æ¸Þ¸®Ä« ±¹°¡º°
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • Æä·ç
    • Ä¥·¹
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ºÎ¹®º°
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ±¹°¡º° ¸®½ºÆ®
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • À̽º¶ó¿¤
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦8Àå ¿ïÇ÷¼º½ÉºÎÀü Ä¡·á ±â±â ±â¾÷ °æÀï ±¸µµ

  • ¿ïÇ÷¼º½ÉºÎÀü Ä¡·á ±â±â ½ÃÀå °æÀï
  • Á¦ÈÞ/Çù·Â/ÇÕÀÇ
  • ÇÕº´¡¤Àμö
  • ½ÅÁ¦Ç° ¹ß¸Å
  • ±âŸ °³¹ß

Á¦9Àå ±â¾÷ °³¿ä

  • »óÀ§ ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®
  • ½ÃÀå ÁýÁßµµ
  • Abbott Laboratories
  • Biotronik SE & Co. KG
  • Boston Scientific Corporation
  • Koninkilijke Philips N.V.
  • Lepu Medical Technology Co. Ltd.
  • LivaNova PLC
  • Medico S.P.A.
  • Medtronic Plc
  • MicroPort Scientific Corporation
  • Oscor Inc.
  • Schiller AG
  • Shree Pacetronix Ltd.
  • St. Jude Medical Inc.
  • Stryker Corporation
  • Terumo Corporation
KSA 24.08.01

The global demand for Congestive Heart Failure Treatment Device Market is presumed to reach the market size of nearly USD 52.14 Billion by 2032 from USD 28.22 Billion in 2023 with a CAGR of 7.06% under the study period 2024-2032.

Congestive Heart Failure (CHF) treatment devices encompass a diverse range of medical devices specifically designed to manage and improve the symptoms of heart failure. These devices play a crucial role in providing therapeutic support to patients with CHF, a chronic condition in which the heart struggles to efficiently pump blood, leading to fluid accumulation in the lungs other areas of the body. The primary goal of congestive heart failure treatment devices is to enhance cardiac function, alleviate symptoms, and enhance patients' overall quality of life.

MARKET DYNAMICS

The CHF treatment device market is witnessing significant growth driven by the increasing prevalence of heart failure globally, particularly among elderly populations. As life expectancy rises and lifestyles evolve, the incidence of heart failure continues to escalate, necessitating advanced treatment options, including implantable devices such as pacemakers, implantable cardioverter-defibrillators (ICDs), and cardiac resynchronization therapy (CRT) devices. Technological advancements in cardiac care are also pivotal drivers of market growth. Innovations such as miniaturization of devices, wireless connectivity for remote monitoring, and improved battery life are enhancing the efficacy and usability of congestive heart failure treatment devices. These advancements improve patient outcomes by providing real-time data to healthcare providers and contribute to better management of chronic conditions through personalized and timely interventions.

Moreover, favorable reimbursement policies and increasing healthcare expenditure are bolstering market expansion. Governments and healthcare organizations increasingly recognize the cost-effectiveness of preventive measures and advanced treatment options for managing chronic diseases like heart failure, thereby supporting the adoption of congestive heart failure treatment devices. However, the high initial costs associated with device implantation and maintenance and stringent regulatory requirements for device approval and patient safety pose barriers to market entry for smaller congestive heart failure treatment device manufacturers.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Congestive Heart Failure Treatment Device. The growth and trends of Congestive Heart Failure Treatment Device industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Congestive Heart Failure Treatment Device market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product

  • Defibrillators (Implantable cardioverter defibrillators (ICDs) (Transvenous ICD (Single-chamber ICDs Dual-chamber ICDs), Subcutaneous ICD))
  • External Cardioverter Defibrillator (Manual External Defibrillator, Automated External Defibrillator (Semi-Automated External Defibrillator, Fully Automated External Defibrillator), Wearable External Cardioverter Defibrillator)
  • Pacemakers (Implantable Pacemakers, External Pacemakers)
  • Cardiac Resynchronization Therapy Devices (Cardiac Resynchronization Therapy-Defibrillators (CRT-D) ( MRI Compatible CRT-D Devices, Conventional CRT-D Devices), Cardiac Resynchronization Therapy-Pacemakers (CRT-P) (MRI Compatible CRT-P Devices, Conventional CRT-P Devices))
  • Ventricular Assist Devices (VADs) (Left Ventricular Assist Devices (LVADs), Right Ventricular assist Devices (RVADs), Biventricular Assist Devices (BIVADs), Percutaneous Ventricular Assist Devices (PVADs), Total Artificial Heart)
  • Other Products

By End-Use

  • Hospitals
  • Cardiac Clinics
  • Ambulatory Surgical Centers
  • Other End-Users

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Congestive Heart Failure Treatment Device market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Congestive Heart Failure Treatment Device market include Abbott Laboratories, Biotronik SE & Co. KG, Boston Scientific Corporation, Koninkilijke Philips N.V., Lepu Medical Technology Co. Ltd., LivaNova PLC, Medico S.P.A., Medtronic Plc, MicroPort Scientific Corporation, Oscor Inc., Schiller AG, Shree Pacetronix Ltd., St. Jude Medical Inc., Stryker Corporation, Terumo Corporation. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. CONGESTIVE HEART FAILURE TREATMENT DEVICE - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Product
    • 3.7.2 Market Attractiveness Analysis By End-Use
    • 3.7.3 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET ANALYSIS BY PRODUCT

  • 5.1. Overview By Product
  • 5.2. Historical and Forecast Data Analysis By Product
  • 5.3. Defibrillators (Implantable cardioverter defibrillators (ICDs) (Transvenous ICD (Single-chamber ICDs Dual-chamber ICDs), Subcutaneous ICD)) Historic and Forecast Sales By Regions
  • 5.4. External Cardioverter Defibrillator (Manual External Defibrillator, Automated External Defibrillator (Semi-Automated External Defibrillator, Fully Automated External Defibrillator), Wearable External Cardioverter Defibrillator) Historic and Forecast Sales By Regions
  • 5.5. Pacemakers (Implantable Pacemakers, External Pacemakers) Historic and Forecast Sales By Regions
  • 5.6. Cardiac Resynchronization Therapy Devices (Cardiac Resynchronization Therapy-Defibrillators (CRT-D) ( MRI Compatible CRT-D Devices, Conventional CRT-D Devices), Cardiac Resynchronization Therapy-Pacemakers (CRT-P) (MRI Compatible CRT-P Devices, Conventional CRT-P Devices)) Historic and Forecast Sales By Regions
  • 5.7. Ventricular Assist Devices (VADs) (Left Ventricular Assist Devices (LVADs), Right Ventricular assist Devices (RVADs), Biventricular Assist Devices (BIVADs), Percutaneous Ventricular Assist Devices (PVADs), Total Artificial Heart) Historic and Forecast Sales By Regions
  • 5.8. Other Products Historic and Forecast Sales By Regions

6. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET ANALYSIS BY END-USE

  • 6.1. Overview By End-Use
  • 6.2. Historical and Forecast Data Analysis By End-Use
  • 6.3. Hospitals Historic and Forecast Sales By Regions
  • 6.4. Cardiac Clinics Historic and Forecast Sales By Regions
  • 6.5. Ambulatory Surgical Centers Historic and Forecast Sales By Regions
  • 6.6. Other End-Users Historic and Forecast Sales By Regions

7. GLOBAL CONGESTIVE HEART FAILURE TREATMENT DEVICE MARKET ANALYSIS BY GEOGRAPHY

  • 7.1. Regional Outlook
  • 7.2. Introduction
  • 7.3. North America Sales Analysis
    • 7.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 7.3.2 North America By Segment Sales Analysis
    • 7.3.3 North America By Country Sales Analysis
    • 7.3.4 United States Sales Analysis
    • 7.3.5 Canada Sales Analysis
    • 7.3.6 Mexico Sales Analysis
  • 7.4. Europe Sales Analysis
    • 7.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 7.4.2 Europe By Segment Sales Analysis
    • 7.4.3 Europe By Country Sales Analysis
    • 7.4.4 United Kingdom Sales Analysis
    • 7.4.5 France Sales Analysis
    • 7.4.6 Germany Sales Analysis
    • 7.4.7 Italy Sales Analysis
    • 7.4.8 Russia Sales Analysis
    • 7.4.9 Rest Of Europe Sales Analysis
  • 7.5. Asia Pacific Sales Analysis
    • 7.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 7.5.2 Asia Pacific By Segment Sales Analysis
    • 7.5.3 Asia Pacific By Country Sales Analysis
    • 7.5.4 China Sales Analysis
    • 7.5.5 India Sales Analysis
    • 7.5.6 Japan Sales Analysis
    • 7.5.7 South Korea Sales Analysis
    • 7.5.8 Australia Sales Analysis
    • 7.5.9 South East Asia Sales Analysis
    • 7.5.10 Rest Of Asia Pacific Sales Analysis
  • 7.6. Latin America Sales Analysis
    • 7.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 7.6.2 Latin America By Segment Sales Analysis
    • 7.6.3 Latin America By Country Sales Analysis
    • 7.6.4 Brazil Sales Analysis
    • 7.6.5 Argentina Sales Analysis
    • 7.6.6 Peru Sales Analysis
    • 7.6.7 Chile Sales Analysis
    • 7.6.8 Rest of Latin America Sales Analysis
  • 7.7. Middle East & Africa Sales Analysis
    • 7.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 7.7.2 Middle East & Africa By Segment Sales Analysis
    • 7.7.3 Middle East & Africa By Country Sales Analysis
    • 7.7.4 Saudi Arabia Sales Analysis
    • 7.7.5 UAE Sales Analysis
    • 7.7.6 Israel Sales Analysis
    • 7.7.7 South Africa Sales Analysis
    • 7.7.8 Rest Of Middle East And Africa Sales Analysis

8. COMPETITIVE LANDSCAPE OF THE CONGESTIVE HEART FAILURE TREATMENT DEVICE COMPANIES

  • 8.1. Congestive Heart Failure Treatment Device Market Competition
  • 8.2. Partnership/Collaboration/Agreement
  • 8.3. Merger And Acquisitions
  • 8.4. New Product Launch
  • 8.5. Other Developments

9. COMPANY PROFILES OF CONGESTIVE HEART FAILURE TREATMENT DEVICE INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Market Concentration Rate
  • 9.3. Abbott Laboratories
    • 9.3.1 Company Overview
    • 9.3.2 Company Revenue
    • 9.3.3 Products
    • 9.3.4 Recent Developments
  • 9.4. Biotronik SE & Co. KG
    • 9.4.1 Company Overview
    • 9.4.2 Company Revenue
    • 9.4.3 Products
    • 9.4.4 Recent Developments
  • 9.5. Boston Scientific Corporation
    • 9.5.1 Company Overview
    • 9.5.2 Company Revenue
    • 9.5.3 Products
    • 9.5.4 Recent Developments
  • 9.6. Koninkilijke Philips N.V.
    • 9.6.1 Company Overview
    • 9.6.2 Company Revenue
    • 9.6.3 Products
    • 9.6.4 Recent Developments
  • 9.7. Lepu Medical Technology Co. Ltd.
    • 9.7.1 Company Overview
    • 9.7.2 Company Revenue
    • 9.7.3 Products
    • 9.7.4 Recent Developments
  • 9.8. LivaNova PLC
    • 9.8.1 Company Overview
    • 9.8.2 Company Revenue
    • 9.8.3 Products
    • 9.8.4 Recent Developments
  • 9.9. Medico S.P.A.
    • 9.9.1 Company Overview
    • 9.9.2 Company Revenue
    • 9.9.3 Products
    • 9.9.4 Recent Developments
  • 9.10. Medtronic Plc
    • 9.10.1 Company Overview
    • 9.10.2 Company Revenue
    • 9.10.3 Products
    • 9.10.4 Recent Developments
  • 9.11. MicroPort Scientific Corporation
    • 9.11.1 Company Overview
    • 9.11.2 Company Revenue
    • 9.11.3 Products
    • 9.11.4 Recent Developments
  • 9.12. Oscor Inc.
    • 9.12.1 Company Overview
    • 9.12.2 Company Revenue
    • 9.12.3 Products
    • 9.12.4 Recent Developments
  • 9.13. Schiller AG
    • 9.13.1 Company Overview
    • 9.13.2 Company Revenue
    • 9.13.3 Products
    • 9.13.4 Recent Developments
  • 9.14. Shree Pacetronix Ltd.
    • 9.14.1 Company Overview
    • 9.14.2 Company Revenue
    • 9.14.3 Products
    • 9.14.4 Recent Developments
  • 9.15. St. Jude Medical Inc.
    • 9.15.1 Company Overview
    • 9.15.2 Company Revenue
    • 9.15.3 Products
    • 9.15.4 Recent Developments
  • 9.16. Stryker Corporation
    • 9.16.1 Company Overview
    • 9.16.2 Company Revenue
    • 9.16.3 Products
    • 9.16.4 Recent Developments
  • 9.17. Terumo Corporation
    • 9.17.1 Company Overview
    • 9.17.2 Company Revenue
    • 9.17.3 Products
    • 9.17.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦